---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-033437"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2024-07-30T23:59:59+00:00"
generated_at: "2026-05-31T15:16:35.079926+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Nasdaq grants Avalo Therapeutics 180-day extension to regain equity compliance

## Summary
- Reported stockholders' equity of negative $112.5M as of March 31, 2024, falling short of Nasdaq's $2.5M minimum.
- Received Nasdaq Staff deficiency notice on May 20, 2024 for non-compliance with Listing Rule 5550(b)(1).
- On July 29, 2024, Nasdaq granted a 180-day extension to November 18, 2024 to regain compliance.
- Company submitted a compliance plan; no assurance it will regain compliance by the deadline.

## SEC filing metadata
- accession: 0001628280-24-033437
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2024-07-30T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000162828024033437/0001628280-24-033437-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000162828024033437/avtx-20240729.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-033437
- JSON: https://secwatch.observer/filing/0001628280-24-033437.json
- Plain text: https://secwatch.observer/filing/0001628280-24-033437.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.